GlassScriptPhysician profile
Philip Favia
NPI 1295729564
$12,013.83
in general payments reported to CMS, 2019-2025
45 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $1,337 · 2021: $1,193 · 2022: $1,830 · 2023: $1,838 · 2024: $1,896 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,999 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,998.92 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,576.34 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,672.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,615.57 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Lilly USA, LLC | $1,586.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,078.84 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Glaxosmithkline, LLC. | $1,012.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Pfizer INC. | $339.86 | 2023-2025 | |
| Boston Scientific Corporation | $248.29 | 2020-2024 | Watchman Access System |
| Abbvie INC. | $200.49 | 2019-2023 | |
| Amarin Pharma, INC. | $190.37 | 2019-2023 | |
| Exact Sciences Corporation | $170.06 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $163.13 | 2020-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $124.27 | 2019-2025 | |
| Medtronic, INC. | $86.45 | 2022-2025 | Venaseal, Intellis Adaptivestim |
| Corium, LLC | $84.49 | 2022-2024 | Azstarys |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Favia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.